Endogenous fungal endophthalmitis: risk factors, clinical course, and visual outcome in 13 patients.
candida endophthalmitis
endogenous endophthalmitis
endogenous fungal endophthalmitis
endophthalmitis
fungal endophthalmitis
Journal
International journal of ophthalmology
ISSN: 2222-3959
Titre abrégé: Int J Ophthalmol
Pays: China
ID NLM: 101553860
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
04
2020
accepted:
15
06
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
21
1
2021
Statut:
epublish
Résumé
To analyze the risk factors, ophthalmological features, treatment modalities and their effect on the visual outcome in patients with endogenous fungal endophthalmitis (EFE). Data retrieved from the medical files included age at presentation to the uveitis clinic, gender, ocular symptoms and their duration before presentation, history of fever, eye affected, anatomical diagnosis and laboratory evidence of fungal infection. Medical therapy recorded included systemic antifungal therapy and its duration, use of intravitreal antifungal agents and use of oral/intravitreal steroids. Surgical procedures and the data of ophthalmologic examination at presentation and at last follow-up were also collected. Included were 13 patients (20 eyes, mean age 58y). Ten patients presented after gastrointestinal or urological interventions and two presented after organ transplantation. In one patient, there was no history of previous intervention. Diagnostic vitrectomy was performed in 16 eyes (80%) and vitreous cultures were positive in 10 of the vitrectomized eyes (62.5%). In only 4 patients (31%), blood cultures were positive. All patients received systemic antifungal therapy. Sixteen eyes (80%) received intravitreal antifungal agent with voriconazole being the most commonly used. Visual acuity (VA) improved from 0.9±0.9 at initial exam to 0.5±0.8 logMAR at last follow-up ( High index of suspicion in patients with inciting risk factors is essential because of the low yield of blood cultures and the good general condition of patients at presentation. Visual prognosis is improved with the prompt institution of systemic and intravitreal pharmacotherapy and the immediate surgical intervention. Oral±local steroids could be considered in cases of prolonged or marked inflammatory responses in order to hasten control of inflammation and limit ocular complications.
Identifiants
pubmed: 33469490
doi: 10.18240/ijo.2021.01.14
pii: ijo-14-01-097
pmc: PMC7790672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97-105Informations de copyright
International Journal of Ophthalmology Press.
Références
Chang Gung Med J. 2002 Nov;25(11):778-82
pubmed: 12553368
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Ocul Immunol Inflamm. 2018;26(4):491-495
pubmed: 29768116
Arch Ophthalmol. 2004 Jan;122(1):42-7
pubmed: 14718293
Arq Bras Oftalmol. 2017 Jun;80(3):196-198
pubmed: 28832730
Arch Ophthalmol. 1995 Dec;113(12):1479-96
pubmed: 7487614
JAMA Ophthalmol. 2017 Jun 1;135(6):534-540
pubmed: 28426852
Mycopathologia. 2014 Jun;177(5-6):223-40
pubmed: 24789109
Ophthalmic Surg Lasers Imaging. 2011 Dec 16;42 Online:e132-4
pubmed: 22165949
Br J Ophthalmol. 1986 Sep;70(9):657-61
pubmed: 3756121
Jpn J Ophthalmol. 2001 Mar-Apr;45(2):181-6
pubmed: 11313052
N Engl J Med. 2016 Feb 25;374(8):794-5
pubmed: 26933864
Clin Microbiol Rev. 2017 Jul;30(3):597-613
pubmed: 28356323
Ocul Immunol Inflamm. 2019;27(5):747-755
pubmed: 29993300
Croat Med J. 2001 Dec;42(6):676-8
pubmed: 11740854
J Thorac Dis. 2018 Jun;10(6):3849-3868
pubmed: 30069386
Clin Infect Dis. 2011 Mar 1;52(5):648-53
pubmed: 21239843
J Obstet Gynaecol Res. 2012 Sep;38(9):1220-2
pubmed: 22563724
Expert Rev Anti Infect Ther. 2014 Jul;12(7):731-4
pubmed: 24850393
Am J Ophthalmol. 2012 Jan;153(1):162-6.e1
pubmed: 21917234
Int Ophthalmol. 1993 Jun;17(3):131-5
pubmed: 8262711
Clin Infect Dis. 2016 Feb 15;62(4):e1-50
pubmed: 26679628
Ocul Immunol Inflamm. 2009 May-Jun;17(3):148-52
pubmed: 19585356
Am J Ophthalmol. 1992 May 15;113(5):593-5
pubmed: 1575241
J Ophthalmic Inflamm Infect. 2013 Sep 20;3(1):60
pubmed: 24053550
Ocul Immunol Inflamm. 2018;26(3):358-361
pubmed: 27715366
Middle East Afr J Ophthalmol. 2019 Aug 26;26(2):110-113
pubmed: 31543670
Medicine (Baltimore). 2003 Mar;82(2):97-105
pubmed: 12640186
Arch Ophthalmol. 2004 Nov;122(11):1687-92
pubmed: 15534131
Retina. 1992;12(1):46-51
pubmed: 1565871
Crit Rev Microbiol. 2016 Nov;42(6):905-27
pubmed: 26690853
BMC Res Notes. 2018 Aug 17;11(1):598
pubmed: 30119688
Graefes Arch Clin Exp Ophthalmol. 2005 Dec;243(12):1197-9
pubmed: 16136321
Eye (Lond). 1999 Oct;13 ( Pt 5):660-5
pubmed: 10696322
PLoS One. 2014 Jul 03;9(7):e101510
pubmed: 24991967
JAMA. 2017 Aug 22;318(8):741-742
pubmed: 28829854
Mediterr J Hematol Infect Dis. 2012;4(1):e2012018
pubmed: 22550563